|
|
Phase III Study of Fluorouracil, Leucovorin Calcium, and Irinotecan in Patients With Metastatic, Locally Advanced, or Recurrent Colorectal Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Combination Chemotherapy in Treating Patients With Colorectal Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
Not specified
|
|
|
|
NCI
|
|
|
|
CLB-9864 E-C9864, NCT00006103, C9864
|
|
|
Objectives - Determine the interracial differences in the pharmacokinetics of irinotecan in combination with fluorouracil in terms of SN-38 glucuronidation and biliary index, and gastrointestinal (GI) toxicity in patients with metastatic, locally advanced, or recurrent colorectal cancer.
- Determine if there is a significant relationship between UGT1A1 genotype (promoter and/or coding region mutation) and CYP3A4 promoter genotype, vs GI toxicity, bone marrow toxicity, and pharmacokinetics of irinotecan in this patient population.
Entry Criteria Disease Characteristics:
- Histologically confirmed adenocarcinoma of the colon or rectum
- Metastatic, locally advanced, or recurrent disease
- Patients must have at least 2 generations (parents and grandparents) who
belong to one of the following racial groups:
- Asian or Pacific Islander (e.g., China, Japan, Korea,
the Philippine Islands,
or Samoa)
- Black (originating from the black racial groups of
Africa)
- Hispanic (originating from Mexico, Puerto Rico, Cuba,
Central or South America, or other Spanish culture)
- White (originating from the peoples of Europe, North
Africa, or the Middle
East)
- No patients with parents or grandparents of mixed race or race other
than that
of the patient
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - Prior adjuvant fluorouracil allowed if relapse occurred at
least 6 months after completion of fluorouracil
- At least 4 weeks since prior chemotherapy (6 weeks for
nitrosoureas or mitomycin)
- No prior irinotecan
- No other concurrent chemotherapy
Endocrine therapy: - No concurrent hormones except steroids for adrenal failure,
hormones for nondisease related conditions (e.g., insulin for diabetes),
or intermittent dexamethasone as an antiemetic
- No concurrent prednisone
Radiotherapy: - At least 4 weeks since prior radiotherapy (except to bone or
soft tissue involving less than 25% of bone marrow)
- No concurrent radiotherapy
Surgery: - At least 4 weeks since prior major surgery
Other: - No concurrent phenobarbital, valproate, or
cyclosporine
- None of the following concurrently during first course of
therapy:
- Macrolide antibiotics (e.g., azithromycin, erythromycin,
clarithromycin, troleandomycin, dapsone)
- Azole antibiotics (e.g., fuconazole, miconazole,
itraconazole, ketoconazole)
- Triazobenzodiazepines (e.g., alprazolam, midazolam,
triazolam)
- Antidepressants (e.g., fluoxetine, setraline hydrochloride,
fluoxamine, nefazodone hydrochloride)
- Quinolone antimicrobials (e.g., ciprofloxacin,
ofloxacin)
- Imidazole antibiotics (e.g., clotrimazole)
- Anti-ulcer medications (e.g., omeprazole,
lansoprazole)
- Ethinyl estradiol
- Diltiazem
- Cimetidine hydrochloride
- Cisapride
- Terfenadine
- Rifampin
- Glucocorticoids
- Antiepileptics
- Grapefruit juice
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Granulocyte count at least 1,500/mm3
- Platelet count at least 100,000/mm3
Hepatic: - Bilirubin no greater than 1.5 mg/dL
- AST no greater than 3 times upper limit of normal
Renal: - Creatinine no greater than 1.5 mg/dL
Other: - Not pregnant or nursing
- Fertile patients must use effective contraception
Expected Enrollment A total of 400 patients (100 per stratum) will be accrued for this study
within 3 years. Outline Patients are stratified according to race (Asian or Pacific Islander vs
black vs Hispanic vs white). Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV,
and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks
for a total of 5 courses in the absence of disease progression or unacceptable
toxicity. Patients are followed every 3 months for 1 year and then every 6 months
thereafter.
Trial Contact Information
Trial Lead Organizations Cancer and Leukemia Group B | | | Brian Leyland-Jones, MD, Protocol chair(Contact information may not be current) | | | |
Eastern Cooperative Oncology Group | | | Sridhar Mani, MD, Protocol chair | | | |
Registry Information | | Official Title | | Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11 | | Trial Start Date | | 2000-07-15 | | Registered in ClinicalTrials.gov | | NCT00006103 | | Date Submitted to PDQ | | 2000-06-28 | | Information Last Verified | | 2007-02-08 | | NCI Grant/Contract Number | | CA31946 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|